Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 5/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591031 | 0.88 | CSNK1D (0.41) | CSNK1DCSNK1EPTGS2EGFRFLT3 | |
| SCHEMBL4438500 | 0.88 | CSNK1D (0.44) | CSNK1DCSNK1ENR2F2EGFRFLT3 | |
| SCHEMBL1590830 | 0.88 | ABL1 (0.48) | CSNK1DCSNK1ENR2F2EGFRFLT3 | |
| SCHEMBL27799100 | 0.85 | NR2F2 (0.42) | CSNK1DCSNK1ENR2F2EGFRFLT3 | |
| SCHEMBL1591184 | 0.79 | FLT3 (0.62) | PTGS2EGFRFLT3PDGFRA | |
| SCHEMBL1590654 | 0.78 | ABL1 (0.48) | CSNK1DCSNK1ENR2F2EGFRFLT3 | |
| SCHEMBL1591791 | 0.78 | CSNK1D (0.48) | CSNK1DCSNK1EEGFRFLT3PDGFRA | |
| SCHEMBL1591728 | 0.78 | SRC (0.46) | CSNK1DCSNK1ENR2F2EGFRABL1 | |
| SCHEMBL1591359 | 0.77 | ABL1 (0.47) | CSNK1DCSNK1ENR2F2EGFRFLT3 | |
| SCHEMBL4443143 | 0.76 | CSNK1D (0.43) | CSNK1DCSNK1EEGFRFLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| EP-1656378-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY | IRM LLC (BM) | 2006-05-17 | — | — | EP | claimed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | claimed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | claimed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | CSNK1D 812/4885CSNK1E 500/4885NR2F2 572/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | CSNK1D 1542/4885CSNK1E 1264/4885NR2F2 4642/4885 |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | BMX, LCK, FYN | CSNK1D 812/4885CSNK1E 500/4885NR2F2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.